Log in to save to my catalogue

Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Asso...

Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Asso...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracacademiconefile_A431582978

Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Associated Phospholipase A.sub.2 Enzyme Inhibitor Darapladib in Healthy Chinese Subjects: An Open Label Phase-1 Clinical Trial

About this item

Full title

Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Associated Phospholipase A.sub.2 Enzyme Inhibitor Darapladib in Healthy Chinese Subjects: An Open Label Phase-1 Clinical Trial

Publisher

Public Library of Science

Journal title

PloS one, 2015-10, Vol.10 (10)

Language

English

Formats

Publication information

Publisher

Public Library of Science

More information

Scope and Contents

Contents

Background and Objectives Darapladib is a lipoprotein-associated phospholipase A.sub.2 (Lp-PLA.sub.2) inhibitor. This study evaluated the pharmacokinetics, pharmacodynamics and safety of darapladib in healthy Chinese subjects. Methods Twenty-four subjects received darapladib 160 mg orally, approximately 1 hour after a standard breakfast, as a singl...

Alternative Titles

Full title

Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Associated Phospholipase A.sub.2 Enzyme Inhibitor Darapladib in Healthy Chinese Subjects: An Open Label Phase-1 Clinical Trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_gale_infotracacademiconefile_A431582978

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracacademiconefile_A431582978

Other Identifiers

ISSN

1932-6203

E-ISSN

1932-6203

DOI

10.1371/journal.pone.0139862

How to access this item